全文获取类型
收费全文 | 3982篇 |
免费 | 476篇 |
国内免费 | 137篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 29篇 |
妇产科学 | 36篇 |
基础医学 | 1527篇 |
口腔科学 | 122篇 |
临床医学 | 186篇 |
内科学 | 511篇 |
皮肤病学 | 65篇 |
神经病学 | 248篇 |
特种医学 | 68篇 |
外国民族医学 | 1篇 |
外科学 | 254篇 |
综合类 | 446篇 |
预防医学 | 97篇 |
眼科学 | 37篇 |
药学 | 538篇 |
中国医学 | 102篇 |
肿瘤学 | 318篇 |
出版年
2024年 | 6篇 |
2023年 | 83篇 |
2022年 | 114篇 |
2021年 | 174篇 |
2020年 | 150篇 |
2019年 | 154篇 |
2018年 | 130篇 |
2017年 | 137篇 |
2016年 | 147篇 |
2015年 | 180篇 |
2014年 | 207篇 |
2013年 | 331篇 |
2012年 | 170篇 |
2011年 | 163篇 |
2010年 | 127篇 |
2009年 | 146篇 |
2008年 | 162篇 |
2007年 | 163篇 |
2006年 | 149篇 |
2005年 | 142篇 |
2004年 | 137篇 |
2003年 | 96篇 |
2002年 | 130篇 |
2001年 | 91篇 |
2000年 | 84篇 |
1999年 | 90篇 |
1998年 | 67篇 |
1997年 | 64篇 |
1996年 | 76篇 |
1995年 | 75篇 |
1994年 | 57篇 |
1993年 | 56篇 |
1992年 | 73篇 |
1991年 | 50篇 |
1990年 | 51篇 |
1989年 | 50篇 |
1988年 | 32篇 |
1987年 | 39篇 |
1986年 | 25篇 |
1985年 | 52篇 |
1984年 | 38篇 |
1983年 | 28篇 |
1982年 | 28篇 |
1981年 | 13篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 10篇 |
1975年 | 3篇 |
排序方式: 共有4595条查询结果,搜索用时 15 毫秒
1.
外泌体是一类直径为30~100 nm的圆盘囊泡,其内包含许多组分,诸如复杂RNA和蛋白质等,主要参与细胞间的信号转导。肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)是肿瘤微环境中普遍存在的巨噬细胞,通过对肿瘤生长、免疫逃逸、侵袭和转移、耐药性等多方面的作用影响肿瘤进程。外泌体在肿瘤相关巨噬细胞的招募、极化及抗肿瘤免疫调控等方面发挥着重要的调节功能。同时,TAMs以外泌体为媒介作用于肿瘤细胞,从而构成了外泌体、TAMs与肿瘤细胞之间相互作用的调控通路。综上所述,本文旨在阐明肿瘤细胞与TAMs之间,以外泌体为“桥梁”相互影响的潜在机制,以及靶向肿瘤细胞和TAMs来源的外泌体在恶性肿瘤治疗中的展望。 相似文献
2.
3.
目的:探究顺铂通过引起宫颈癌细胞铁死亡进而诱导肿瘤相关巨噬细胞极化从而抑制宫颈癌细胞耐药性的机制。方法:使用5μmol/L顺铂处理顺铂耐药宫颈癌细胞Hela/R一定时间后,采用qRT-PCR法检测铁死亡相关基因的mRNA表达变化情况;使用ELISA试剂盒和荧光染色法测定铁死亡后的Hela/R细胞释放高迁移率族蛋白1(high mobility group box 1,HMGB1)的情况。将顺铂处理过的Hela/R细胞和M2型小鼠骨髓来源巨噬细胞共培养一定时间后,采用流式细胞术检测巨噬细胞激活情况。将共培养后的巨噬细胞和Hela/R细胞共孵育,采用CCK8法和流式细胞术分别检测肿瘤细胞的存活率和凋亡情况。结果:实验数据显示,顺铂可引起Hela/R细胞的铁死亡,抑制其铁死亡抑制基因Slc40a1、Slc7a11、Slc3a2、Gpx4、Fth1、Blvrb的mRNA表达(P<0.05),上调铁死亡诱发基因Slc5a1、Tfrc的mRNA表达(P<0.01)。铁死亡Hela/R细胞释放损伤相关模式分子HMGB1,诱导M2型肿瘤相关巨噬细胞的CD80、CD86和CD40平均荧光强度提升,增强了肿瘤相关巨噬细胞对Hela/R细胞的杀伤能力。结论:顺铂通过引起宫颈癌细胞的铁死亡激活肿瘤相关巨噬细胞进而达到有效杀伤肿瘤细胞的效果。 相似文献
4.
5.
6.
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, −21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies. 相似文献
7.
8.
Jie Li Megan M. Kaneda Jun Ma Ming Li Ryan M. Shepard Kunal Patel Tomoyuki Koga Aaron Sarver Frank Furnari Beibei Xu Sanjay Dhawan Jianfang Ning Hua Zhu Anhua Wu Gan You Tao Jiang Andrew S. Venteicher Jeremy N. Rich Christopher K. Glass Judith A. Varner Clark C. Chen 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(16)
9.
Qiang Fu Le Xu Yiwei Wang Qi Jiang Zheng Liu Junyu Zhang Quan Zhou Han Zeng Shanyou Tong Tao Wang Yangyang Qi Baoying Hu Hangcheng Fu Huyang Xie Lin Zhou Yuan Chang Yu Zhu Bo Dai Jiejie Xu 《European urology》2019,75(5):752-763
Background
Glutamine addiction is a hallmark of clear cell renal cell carcinoma (ccRCC); yet whether glutamine metabolism impacts local immune surveillance is unclear. This knowledge may yield novel immunotherapeutic opportunities.Objective
To seek a potential therapeutic target in glutamine-addicted ccRCC.Design, setting, and participants
Tumors from ccRCC patients from a Shanghai cohort and ccRCC tumor data from The Cancer Genome Atlas (TCGA) cohort were analyzed. In vivo and in vitro studies were conducted with fresh human ccRCC tumors and murine tumor cells.Outcome measurements and statistical analysis
Immune cell numbers and functions were analyzed by flow cytometry. Glutamine and cytokine concentrations were determined. Survival was compared between different subpopulations of patients using Kaplan-Meier and Cox regression analyses.Results and limitations
We found that in ccRCC, high interleukin (IL)-23 expression was significantly associated with poor survival in both TCGA (overall survival [OS] hazard ratio [HR] = 2.04, cancer-specific survival [CSS] HR = 2.95; all p < 0.001) and Shanghai (OS HR = 2.07, CSS HR = 3.92; all p < 0.001) cohorts. IL-23 blockade prolongs the survival of tumor-bearing mice, promotes T-cell cytotoxicity in in vitro cultures of human ccRCC tumors, and augments the therapeutic benefits of anti-PD-1 antibodies. Mechanistically, glutamine consumption by ccRCC tumor cells results in the local deprivation of extracellular glutamine, which induces IL-23 secretion by tumor-infiltrating macrophages via the activation of hypoxia-inducible factor 1α (HIF1α). IL-23 activates regulatory T-cell proliferation and promotes IL-10 and transforming growth factor β expression, thereby suppressing tumor cell killing by cytotoxic lymphocytes. The positive correlations between glutamine metabolism, IL-23 levels, and Treg responses are confirmed in both TCGA cohort and tumors from Shanghai ccRCC patients. Study limitations include the unclear impacts of glutamine deprivation and IL-23 on other immune cells.Conclusions
Macrophage-secreted IL-23 enhanced Treg functions in glutamine-addicted tumors; thus, IL-23 is a promising target for immunotherapy in ccRCC.Patient summary
In this study, we analyzed the immune components in glutamine-addicted clear cell renal cell carcinoma (ccRCC) tumors from two patient cohorts and conducted both in vitro and in vivo studies. We found that ccRCC tumor cell-intrinsic glutamine metabolism orchestrates immune evasion via interleukin (IL)-23, and IL-23–high patients had significantly poorer survival than IL-23–low patients. IL-23 should thus be considered a therapeutic target in ccRCC, either alone or in combination with immune checkpoint inhibitors. 相似文献10.